<DOC>
	<DOCNO>NCT02571972</DOCNO>
	<brief_summary>This study seek evaluate effect topical aqueous suppression anatomic functional response intravitreal anti-vascular endothelial growth factor ( VEGF ) injection non-responders wet age-related macular degeneration .</brief_summary>
	<brief_title>Dorzolamide-timolol Drops With Injections Treat AMD , RVO DME .</brief_title>
	<detailed_description>Intravitreal anti-vascular endothelial growth factor ( VEGF ) agent , include bevacizumab , ranibizumab , aflibercept , become gold standard treatment neovascular age-related macular degeneration ( AMD ) . Various treatment modality use agent propose , include monthly , pro nata , treat-and-extend philosophy . Despite frequent consistent treatment anti-VEGF therapy , subset patient incomplete non-responders persistent evidence exudation spectral-domain optical coherence tomography ( SD-OCT ) , include subretinal fluid ( SRF ) and/or intraretinal edema . While clearance intravitreal anti-VEGF drug completely understand , study suggest outflow anterior chamber may contribute . We hypothesize decrease aqueous production , outflow may also reduce could delay clearance intravitreal drug . As result , choose topical dorzolamide-timolol since potent aqueous suppressant readily available due common use treatment glaucoma . The current study aim evaluate efficacy topical dorzolamide-timolol anatomic visual outcome anti-VEGF non-responders neovascular AMD . Significance : The result study help delineate whether topical aqueous suppression may useful adjuvant therapy patient receive chronic intravitreal anti-VEGF injection .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<criteria>1 . Patient Wills Eye Hospital Retina Service and/or Mid Atlantic Retina . 2 . Volunteer patient age 18 year old . 3 . Healthy enough participate study . 4 . Willing able consent participation study . 5 . Diagnosis wet agerelated macular degeneration 6 . Prior treatment least 4 injection antiVEGF agent past 6 month persistent intraretinal and/or subretinal fluid SDOCT visit period 7 . Injection antiVEGF agent least two visit prior study enrollment 8 . Fixed interval least two visit prior study enrollment 1 . History uveitis 2 . Any ophthalmic surgery within previous 6 month , include cataract extraction . 3 . Any history vitrectomy 4 . History glaucoma drop usage prior glaucoma surgery 5 . Systemic diuretic corticosteroid usage 6 . Any contraindication ( bradycardia , decompensated heart failure , reactive 7. airway disease ) topical use betablocker 8 . Any history sulfonamide allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>dorzolamide-timolol</keyword>
	<keyword>topical aqueous suppression</keyword>
	<keyword>neovascular age-related macular degeneration</keyword>
	<keyword>macular edema</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>anti-vascular endothelial growth factor</keyword>
</DOC>